Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis Pharmaceuticals Buy Rating Affirmed on Strong Clinical Data and Robust Pipeline Potential
Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Ionis Pharmaceuticals (IONS) and 89bio (ETNB)
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) wa
Biogen Also Drops Collaboration With Ionis on Angelman Syndrome Candidate
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for amyotrop
Shares of Biogen and Ionis Pharmaceuticals Are Trading Lower After the Company Discontinued Development of ALS Candidate BIIB105.
Shares of Biogen and Ionis Pharmaceuticals Are Trading Lower After the Company Discontinued Development of ALS Candidate BIIB105.
Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk
1152 ET - Ionis Pharmaceuticals will advance its ION582 candidate for the genetic disorder Angelman syndrome after partner Biogen elected not to exercise its option to license and lead development of
Bojian and Ionis will stop developing ALS drugs
GLONGHUI, May 16 | Bojian and Ionis Pharmaceuticals said on Thursday that they will stop developing an experimental therapy (ALS) to treat amyotrophic lateral sclerosis (ALS). In an early to mid-term study, the patient's condition did not improve. ALS, commonly known as Lugaray's disease, is a rare and fatal neurodegenerative disease that affects the autonomous control of hands and feet and causes breathing difficulties. The two companies' drug BIIB105 did not succeed in significantly reducing neurodegeneration or improving functional indicators such as breathing in patients. In the US and Europe, around 60,000 people are affected by ALS
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study
Ionis Pharmaceuticals (IONS) said Thursday that topline data from a phase 1/2a study showed that ION582 improved cognition, communication, and motor function in patients with Angelman syndrome. The st
Sector Update: Health Care Stocks Steady Premarket Thursday
Health care stocks were steady premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Arvinas (ARVN) shares were up more than
UPDATE 1-Biogen, Ionis to Discontinue Development of ALS Drug
Ionis And Biogen Say Development Of BIIB105 Will Be Discontinued Based On Data From Phase 1/2 Study
Ionis And Biogen Say Development Of BIIB105 Will Be Discontinued Based On Data From Phase 1/2 Study
Ionis Pharmaceuticals Announced Topline Data From HALOS Phase 1/2A Open-label Study Of ION582 In Angelman Syndrome, ION582 Was Safe And Well Tolerated In The Study And Showed Encouraging And Consistent Benefits
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patientsION582 was safe and well tolerated at all dose levelsIonis plans to move ION582 into pivotal
Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers
-Danvatirsen is now being evaluated in two clinical trials for head and neck and AML/MDS cancers- LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Flamingo Therap
Ionis to Host 2024 Virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ...
Ionis Pharmaceuticals: A Strong Buy on Diverse Pipeline and Positive Clinical Milestones
Here's What Analysts Are Forecasting For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) After Its First-Quarter Results
Last week, you might have seen that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly result to the market. The early response was not positive, with shares down 6.8% to US$40.16 in the
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratin
No Data